PROTHENA CORP PUBLIC LTD CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PROTHENA CORP PUBLIC LTD CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $256.0K | Mar 3, 2020 |
| FY2019 | Sep 30, 2019 | $205.0K | Mar 3, 2020 |
| FY2019 | Jun 30, 2019 | $167.0K | Mar 3, 2020 |
| FY2019 | Mar 31, 2019 | $186.0K | Mar 3, 2020 |
| FY2019 | Dec 31, 2018 | $194.0K | Mar 3, 2020 |
| FY2019 | Sep 30, 2018 | $255.0K | Mar 3, 2020 |
| FY2019 | Jun 30, 2018 | $279.0K | Mar 3, 2020 |
| FY2019 | Mar 31, 2018 | $227.0K | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $229.0K | Mar 15, 2019 |
| FY2018 | Sep 30, 2017 | $219.0K | Mar 15, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.68M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $135.16M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $91.37M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $53.91M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $200.58M | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $360.0K | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $157.0K | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $195.0K | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $141.0K | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $256.0K | Feb 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($244.09M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($122.31M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($147.03M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($116.95M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $66.98M | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | ($30.72M) | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | ($30.58M) | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | ($26.28M) | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | ($23.57M) | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | ($21.55M) | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($214.64M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($154.56M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($191.04M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($131.56M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $71.98M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($112.73M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($85.70M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($158.86M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($155.25M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($159.54M) | Mar 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.85M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $222.52M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $220.57M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $135.56M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $82.28M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $74.88M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $50.84M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $101.18M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $134.55M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $119.53M | Mar 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($163.58M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($150.05M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($133.91M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($108.82M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $92.61M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($80.36M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($52.97M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($28.28M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($131.18M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($116.25M) | Mar 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $326.80M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $547.11M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $696.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $758.04M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $609.37M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $332.98M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $419.27M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $498.80M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $496.33M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $459.98M | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.33M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $60.18M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $135.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $135.99M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $143.32M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $148.97M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $146.35M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $175.80M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $89.14M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $94.57M | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.47M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $486.93M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $561.37M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $622.04M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $466.04M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $184.01M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $272.92M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $323.00M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $407.19M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $365.40M | Feb 26, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.35B) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.10B) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($980.03M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($833.00M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($716.05M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($783.03M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($671.89M) | Feb 26, 2021 |
| FY2019 | Jan 1, 2019 | ($594.21M) | Mar 3, 2020 |
| FY2019 | Dec 31, 2018 | ($598.00M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($442.35M) | Mar 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $307.53M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $471.39M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $618.83M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $710.41M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $579.09M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $295.38M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $375.72M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $427.66M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $417.62M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $386.92M | Mar 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 53.83M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 53.83M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 53.68M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 52.10M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 46.66M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 39.92M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 39.90M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 39.86M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 38.48M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 34.75M | Feb 26, 2018 |